Related Experiment Videos
Clinical experience with a new solvent detergent-treated intravenous immunoglobulin free of hypotensive effects
K Chidwick1, P Matejtschuk, E Gascoigne
1Bio Products Laboratory, Elstree, UK. KC22113@bpl.co.uk
Vox Sanguinis
|March 16, 2000
Objective:
To see if modifications to the processing of intravenous immunoglobulin to include a virus inactivation stage alter immunoglobulin G (IgG) resulting in hypotension in patients.
Methods:
Clinical trials were done involving extensive patient monitoring during infusion: in vitro - testing for markers of hypotension, and in vivo - an animal model which closely simulates clinical use.
Results:
No hypotensive response was seen in the animal model or clinical trial.
Conclusions:
The production process used does not damage IgG or create vaso-active kinins as the preparation was free of hypotensive effects.